Press Release FeedGet the RSS feed
Menu

Business Wire

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Jefferies Financial Group

HAYWARD, Calif., October 22, 2026--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences has granted the underwriters a 30-day option to purchase up to 2,142,857 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 23, 2026, subject to customary closing conditions.

Jefferies, Leerink Partners, TD Cowen, Evercore ISI and Mizuho are acting as joint book-running managers for the offering.

A shelf registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, and automatically became effective upon filing. This offering is being made solely by means of a prospectus. A copy of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, a copy of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by telephone at (877) 821-7388, or by email at [email protected]; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected]; or TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

  1. Biotech & pharmaCity Therapeutics Announces Pricing of Upsized Initial Public OfferingCompanies: Jefferies Financial GroupCity Therapeutics Announces Pricing of Upsized Initial Public Offering
  2. FinanceŌURAŌURA Announces Launch of Initial Public OfferingCompanies: Jefferies Financial GroupMorgan StanleySAN FRANCISCO, September 21, 2026--ŌURA, a leading health intelligence platform and maker of the world’s smallest smart ring, today announced that it has launched its initial public offering of 50,000,000 shares of its common stock. The offering consists of 13,500,000 shares offered by Oura and 36,500,000 shares offered by certain of Oura’s existing stockholders. In addition, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 7,500,000 share
  3. FinanceCoVolt Power, Inc.CoVolt Power Announces Public Filing of Registration Statement for Proposed Initial Public OfferingCompanies: Jefferies Financial GroupHOUSTON, August 21, 2026--CoVolt Power, Inc. ("CoVolt Power" or the "Company"), today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of shares of its Class A common stock.
  4. FinanceAres Acquisition Corporation IIIAres Acquisition Corporation III Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing August 20, 2026Companies: Jefferies Financial GroupNEW YORK, August 20, 2026--Ares Acquisition Corporation III (NYSE: AAC.U) (the "Company"), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses, today announced that, commencing August 20, 2026, holders of the 39,500,000 units sold in the Company’s initial public offering (the "Units"), completed on July 1, 2026, may elect to separately trade the Class A ordinary shares and warrants included in the Units. Those Units not separate
  5. FinanceSilence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSsCompanies: Jefferies Financial GroupMorgan StanleyLONDON, August 14, 2026--Silence Therapeutics plc, (Nasdaq: SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which incl